1-6 of 6
Marjo Hahka-Kemppinen
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Preliminary Results from a Phase I Study of HMPL-523, a Selective Oral Syk Inhibitor, in Patients with Relapsed or Refractory Lymphoma

Paolo Strati, Dominik Chraniuk, Eva González-Barca, Michal Taszner, Rathi Pillai, Caly Chien, Shivani Nanda, Mark Rudinski, Vijayvel Jayaprakash, Marjo Hahka-Kemppinen, Marek Kania
Journal: Blood
Blood (2021) 138 (Supplement 1): 2432.
https://doi.org/10.1182/blood-2021-145641
Published: 2021
Journal Articles

A Phase 1, Open-Label, Multicenter Study of HMPL-306 in Advanced Hematological Malignancies with Isocitrate Dehydrogenase (IDH) Mutations

Anu Doraiswamy, Vijayvel Jayaprakash, Marek Kania, Marjo Hahka-Kemppinen, Zhao Yang, Mark Rudinski, Farhad Ravandi
Journal: Blood
Blood (2021) 138 (Supplement 1): 4438.
https://doi.org/10.1182/blood-2021-145636
Published: 2021
Journal Articles

A Phase 1 Study of HMPL-523, Highly Selective and Potent a Small Molecule Inhibitor of Spleen Tyrosine Kinase in Patients with Relapsed or Refractory Lymphoma

Tunde Lawrence, MD PhD, Marjo Hahka-Kemppinen, MD, Paolo Strati, MD, Marek Kania, MD MBA
Journal: Blood
Blood (2020) 136 (Supplement 1): 17.
https://doi.org/10.1182/blood-2020-141451
Published: 2020
Journal Articles

A Phase 1 Study of HMPL-689, a Small Molecule, Highly Selective, and Potent Inhibitor of Phosphoinositide 3 Kinase-Delta, in Patients with Relapsed or Refractory Lymphoma

Tunde Lawrence, MD PhD, Marjo Hahka-Kemppinen, MD, Jonathon B. Cohen, MDMS, Marek Kania, MD MBA
Journal: Blood
Blood (2020) 136 (Supplement 1): 17–18.
https://doi.org/10.1182/blood-2020-141465
Published: 2020
Journal Articles

Clinical Activity of Abemaciclib (LY2835219), a Cell Cycle Inhibitor Selective for CDK4 and CDK6, in Patients with Relapsed or Refractory Mantle Cell Lymphoma

Franck Morschhauser, MD PhD, Kamal Bouabdallah, MD, Stephan Stilgenbauer, MD, Catherine Thieblemont, MD PhD, Martin Wolf, MD, Sophie de Guibert, MD, Florian Zettl, MD, Marjo Hahka-Kemppinen, MD PhD, David Xiaohui Wang, MD PhD, Patrick Brueck, MD, Charles Caldwell, MD, Richard Beckmann, PhD, Lawrence Gelbert, PhD, Damien Cronier, PhD, Ji Lin, PhD, Lily Li, MD, Edward M. Chan, MD, Michael Pfreundschuh, Martin Wilhem, MD, Georg Hess, MD
Journal: Blood
Blood (2014) 124 (21): 3067.
https://doi.org/10.1182/blood.V124.21.3067.3067
Published: 2014
Journal Articles

A Phase III Study Of Enzastaurin In Patients With High-Risk Diffuse Large B Cell Lymphoma Following Response To Primary Treatment: The Prelude Trial

Michael Crump, MD FRCPC, Sirpa Leppä, Luis E Fayad, Je-Jung Lee, Alice Di Rocco, MD, Michinori Ogura, MD, PhD, Hans Hagberg, Frederick Schnell, Robert M Rifkin, MD, Andreas Mackensen, Fritz Offner, MD, Lauren Pinter-Brown, MD, Sonali M. Smith, MD, Kensei Tobinai, MD, PhD, Su-Peng Yeh, MD, Jun Zhu, Marjo Hahka-Kemppinen, MD, PhD, Donald Thornton, MD, Peipei Shi, Ph.D., Boris Lin, MD, PhD, Brad S. Kahl, MD, Norbert Schmitz, Kerry J. Savage, MD, MSc, Thomas M Habermann, MD
Journal: Blood
Blood (2013) 122 (21): 371.
https://doi.org/10.1182/blood.V122.21.371.371
Published: 2013